Verily, Alphabet’s life sciences and healthcare division, has raised $300 million in fresh funding to scale its ambitious AI-based healthcare initiatives. The capital will accelerate development of precision diagnostics, predictive analytics platforms, chronic disease management tools, and real-world evidence generation reinforcing Verily’s position as a leader in data-driven, technology-enabled healthcare transformation.
Glimpse:
The $300 million round, supported by strategic investors and existing backers, will fuel expansion of Verily’s AI-powered projects including advanced sensor technologies, machine learning models for early disease detection, digital therapeutics for diabetes and mental health, and integrated platforms for clinical research and population health. The investment supports Verily’s goal of bridging consumer health data with clinical insights to deliver more proactive, personalized, and cost-effective care while advancing regulatory approvals and commercial partnerships.
Verily, the life sciences and healthcare arm of Alphabet, has successfully closed a $300 million funding round to significantly scale its AI-driven healthcare strategy. The investment, announced on February 27, 2026, comes from a mix of strategic healthcare investors, venture funds, and existing partners who share Verily’s vision of using data, AI, and advanced technologies to fundamentally improve human health. This latest infusion brings Verily’s total funding to well over $1 billion and arrives as the company transitions several high-impact projects from research to real-world deployment and commercialization.
The fresh capital will primarily support the acceleration of Verily’s core AI initiatives, including next-generation sensor technologies for continuous health monitoring, machine learning platforms for early detection of chronic conditions (diabetes, cardiovascular disease, respiratory issues), predictive analytics for disease progression and treatment response, and digital therapeutics that combine behavioural interventions with pharmacological approaches. Verily will also expand its efforts in real-world evidence generation, leveraging vast datasets from wearables, EHRs, and clinical studies to derive actionable insights for drug development, care delivery, and public health policy.
A key focus of the investment is on scaling Verily’s integrated platforms that bridge consumer-generated data (from wearables and apps) with clinical-grade information, enabling more proactive and personalized care. This includes enhancements to tools for diabetes management (Project Baseline, Onduo), mental health support, and precision diagnostics in oncology and immunology. The funding will also support regulatory advancements, clinical validation trials, expanded partnerships with health systems, payers, and life sciences companies, and the build-out of secure, scalable cloud infrastructure to handle increasing data volumes while maintaining strict privacy and compliance standards (HIPAA, GDPR, and emerging global regulations).
Verily’s leadership highlighted that the healthcare industry is at an inflection point where AI can move from experimental pilots to enterprise-scale impact reducing costs, improving outcomes, and shifting care from reactive to preventive. The company emphasized that its approach prioritizes ethical AI development, clinician collaboration, bias mitigation, and transparency to build trust among providers, patients, and regulators. The new funding positions Verily to deepen its competitive edge in a rapidly evolving landscape where data-driven insights are becoming central to both clinical decision-making and health system efficiency.
This round reflects strong investor confidence in Verily’s differentiated strategy combining Alphabet’s computational power with deep life sciences expertise and underscores the growing momentum behind AI-first healthcare companies capable of delivering measurable impact at scale. Verily plans to announce several new product advancements and partnerships in the coming months as it accelerates toward broader commercialization.
“AI has the power to change how we understand and manage health not just for individuals, but for entire populations. This funding allows us to scale solutions that make care more precise, proactive, and accessible than ever before.”
By
HB Team
Related News
